Neuroscience

FNIH Biomarkers Consortium “clock model” can use a single blood test to estimate the onset of symptoms within three to four years

A global harmonized proteomics dataset of Alzheimer’s, Parkinson’s, and FTD uncovers disease signatures to accelerate diagnostics and therapeutic discovery

Researchers report that dried blood spots can reliably measure p-tau217 and other Alzheimer’s biomarkers in a controlled research setting

The annual “Nature’s 10” list captures how scientists pushed the boundaries of knowledge in 2025

Collaboration brings new hope for patients with multiple sclerosis through expanded access to a clinically validated multi-analyte blood test

Some concussion biomarkers show sex-specific differences

Exploring how precision biomarkers can reveal hidden disease dynamics and drive a new standard of MS care

The findings provide fresh insights into the potential health risks posed by environmental plastics

Study highlights the critical need for early intensive care in influenza-associated acute necrotizing encephalopathy, a severe brain swelling condition

At the ADLM 2025, Roche highlights advances in diagnostics, including digital health solutions, mass spectrometry, and expanded access to testing across care settings

The new “iPSC Platform to Model Alzheimer’s disease Risk” (IPMAR) resource will be made available to researchers worldwide

MS expert Stephanie Buxhoeveden combines personal experience with scientific expertise to explore how biomarkers are transforming MS care

First blood-based in vitro diagnostic test to receive FDA clearance to help identify patients with amyloid pathology associated with Alzheimer’s disease

New test provides less invasive option, reduces reliance on PET scans, and increases diagnosis accessibility

In a proof-of-concept study, the test detected five key biomarkers of Alzheimer’s disease—more than current commercially available blood tests can measure

Even small tissue samples can yield additional insights into a tumor’s biology, immune interactions, and molecular pathways

Prior to the MSDA Test, disease management in MS relied primarily on clinical assessments and MRI

VeraBIND™ Tau is a new noninvasive test that offers 96 percent sensitivity and 90 percent specificity, empowering earlier and more accessible Alzheimer's detection

New treatments are moving away from open surgery and toward minimally invasive techniques

Potential new therapy for childhood brain cancer is effective in infiltrating, killing tumor cells in preclinical models in mice